[GDF15 : un modulateur de l'immunité et biomarqueur prédictif des atteintes cardiovasculaires : une stratégie dans le COVID-19].
Fiche publication
Date publication
septembre 2022
Journal
Annales de cardiologie et d'angeiologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COTTIN Yves, Pr VERGELY Catherine
Tous les auteurs :
Rochette L, Dogon G, Rigal E, Zeller M, Vergely C, Cottin Y
Lien Pubmed
Résumé
In the recently published manuscript entitled "GDF15 a rising modulator of immunity and a strategy in Coronavirus disease 2019 (COVID-19) in relationship with iron metabolism" and we examined the potential properties of Growth and differentiation factor 15 (GDF15) as an emerging modulator of immunity in COVID-19. We commented new aspects of the biology of GDF15 and investigated the potential value of GDF15 as a biomarker. Is GDF15 a biomarker of the inflammatory process and oxidative stress state? Recently, it was reported that 1500 clinical trials related to COVID-19 have been registered, but none have yet found an optimal strategy. In these conditions, more clinical studies are needed before any of these agents can be considered antiviral agents.
Mots clés
Biomarker, COVID-19, Cardiovascular, GDF15, Immunity, biomarqueur, cardiovasculaire, immunité
Référence
Ann Cardiol Angeiol (Paris). 2022 09 16;: